Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer

Michal Mego(Comenius University Bratislava), JM Reuben(The University of Texas MD Anderson Cancer Center), Massimo Cristofanilli(Cornell University), Simone Anfossi(The University of Texas MD Anderson Cancer Center), Mario Giuliano(Regione Campania), Evan N. Cohen(The University of Texas MD Anderson Cancer Center), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Tarun Sanda(Comenius University Bratislava), Vicente Valero(The University of Texas MD Anderson Cancer Center), Naoto T. Ueno(Breast Cancer Care), Tamer M. Fouad(The University of Texas MD Anderson Cancer Center), Hui Gao(The University of Texas MD Anderson Cancer Center), RH Alvarez(The University of Texas MD Anderson Cancer Center), Wendy A. Woodward(The University of Texas MD Anderson Cancer Center), GN Hortobagyi(The University of Texas MD Anderson Cancer Center), Antonio Giordano(University of Siena)
Journal of Cancer
January 1, 2016
10.7150/jca.13098
Cited by 86

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k